Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Association Between Pre-ICU Selective Serotonin Reuptake Inhibitor Use and Delirium in Older Patients With Sepsis: A Study Based on the MIMIC-IV Database.

The Annals of pharmacotherapy·2026

Same journal

Description of Treatment Strategies and Patient Outcomes for Hospitalized Patients With Lyme Carditis.

The Annals of pharmacotherapy·2026

Same journal

Adverse Drug Reactions Associated With Longer All-Oral MDR/XDR-TB Regimens: Prospective Pharmacovigilance Evidence From a High-Burden Tertiary Care Setting in North India.

The Annals of pharmacotherapy·2026

Same journal

Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis.

The Annals of pharmacotherapy·2026

Same journal

Reduced Dose-Direct Oral Anticoagulant Vs Dual Antiplatelet Therapy After Left Atrial Appendage Closure in Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta Analysis.

The Annals of pharmacotherapy·2026

Same journal

Characterization of Antidiabetic Medication Prescribing After Hospital Discharge in US Critically Ill Adults.

The Annals of pharmacotherapy·2026

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Pregabalin-induced hepatotoxicity.

Juan Moll Sendra¹, Teresa Torrecilla Junyent, Maria José Remigia Pellicer

¹Pharmacy Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. juanmoll@alumni.uv.es

The Annals of Pharmacotherapy

|June 10, 2011

Summary

Pregabalin, a medication for neuropathic pain, may cause liver injury. This case report highlights a probable adverse reaction, emphasizing the need for prescriber awareness regarding potential pregabalin-induced hepatotoxicity.

Related Experiment Videos

Last Updated: Jun 1, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Area of Science:

Hepatology
Clinical Pharmacology
Adverse Drug Reactions

Background:

Neuropathic pain is a debilitating condition often managed with medications like pregabalin.
Liver injury is a known potential adverse effect of various drugs, necessitating vigilance in clinical practice.

Observation:

A 59-year-old male with mantle cell lymphoma developed elevated liver enzymes (AST, ALT, GGT) after initiating low-dose pregabalin for neuropathic pain.
The patient also experienced ankle edema, and liver enzyme levels normalized over four months after discontinuing pregabalin.

Findings:

This case suggests a probable idiosyncratic hepatotoxic reaction to pregabalin, supported by Naranjo and CIOMS scales.
Few documented cases of pregabalin-associated liver injury exist, making this report significant.

Implications:

Clinicians should consider pregabalin as a potential cause of acute liver injury, especially in patients with pre-existing liver conditions.
Increased awareness of pregabalin-induced hepatotoxicity is crucial for safe patient management and monitoring.